NEW YORK – Immix Biopharma this week said it plans to address various conditions with its autologous CAR T-cell therapy NXC-201 in what it calls its "other serious diseases" strategy. NXC-201 is a ...

100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS Best responder duration of response was 16.5 months with ...

75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.

I am using the GOAD lab to recreate this issue. In that lab, the machine "CASTELBLACK" allows anonymous login and has a share which allows read access to anonymous users. Using smbclient, I can log in ...

Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...

On Tuesday, Immix Biopharma Inc. (NASDAQ:IMMX) announced that its cell therapy NXC-201 met its primary endpoint of complete response/CR rate in interim results from the US multi-site NEXICART-2 Phase ...